Business
FDA throws wet blanket on Mesoblast’s treatment for bone marrow transplant condition – Business News Australia
Before pivoting to find a treatment for critically ill COVID-19 patients suffering from severe acute respiratory distress syndrome (ARDS), Mesoblast’s (ASX: MSB, NASDAQ: MESO) most advanced business centred on an entirely different ailment.
Before pivoting to find a treatment for critically ill COVID-19 patients suffering from severe acute respiratory distress syndrome (ARDS), Mesoblast’s (ASX: MSB, NASDAQ: MESO) most advanced business centred on an entirely different ailment.
The Melbourne-based company has sought US regulatory approval for its stem cell-based product remestemcel-L in treating graft versus host disease (GvHD) – a potentially life-threatening condition that some people experience after receiving a bone marrow tran…
-
Noosa News21 hours agoMan arrested after mother and 10-year-old girl killed in car crash in Far North Queensland’s Doomadgee
-
Noosa News21 hours agoFraser Bax | Thynne + Macartney – Proctor
-
General21 hours agoTasmanian farmed salmon industry granted emergency federal approval to use florfenicol antibiotic
-
Business20 hours ago3 excellent ASX ETFs to buy for lifelong passive income